Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | UGT2B7 | P16662 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3867493 | 1.00 | MGAM (0.38) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL13760080 | 0.75 | HCAR2 (0.47) | ALDH1A1SMN1; SMN2CYP3A4MAPT | |
| SCHEMBL7591529 | 0.75 | HCAR2 (0.47) | ALDH1A1SMN1; SMN2CYP3A4MAPT | |
| SCHEMBL6647774 | 0.74 | GAA (0.57) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL6708068 | 0.74 | GAA (0.57) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL13760081 | 0.70 | — | — | |
| SCHEMBL13765634 | 0.69 | — | — | |
| SCHEMBL148959 | 0.69 | NR1I2 (0.53) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL148958 | 0.69 | NR1I2 (0.53) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL1203424 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563924-B2 | 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-07-21 | — | — | US | disclosed |
| EP-1816121-B1 | 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-20070203096-A1 | 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-08-30 | — | — | US | disclosed |
| EP-1816121-A1 | 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-08-08 | — | — | EP | disclosed |
| WO-2007057232-A1 | 9-CHLORO-15-DEOXYPROSTAGLANDIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203096-A1 | 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments | PGF, PTGIS, CYP11B2 | MGAM 3358/4885GAA 4402/4885SI 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.